# First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

> **NCT04840784** · PHASE1 · TERMINATED · sponsor: **Shengke Pharmaceuticals Pty Ltd** · enrollment: 9 (actual)

## Conditions studied

- NHL
- Leukemia

## Interventions

- **DRUG:** ETH-155008

## Key facts

- **NCT ID:** NCT04840784
- **Lead sponsor:** Shengke Pharmaceuticals Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-29
- **Primary completion:** 2023-05-02
- **Final completion:** 2023-05-02
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** The reasons for early termination is due to slow recruitment
- **Last updated:** 2023-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04840784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04840784, "First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04840784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*